Compare Newmont Corporation (NEM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Twist Bioscience Corp — how do they compare? Newmont Corporation trades at $93.49 (market cap $95.23B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Newmont Corporation is far larger — about 17.5× Twist Bioscience Corp's market cap, and Newmont Corporation pays a 1.17% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NEM | TWST | |
|---|---|---|
Market Cap | $95.23B | $5.45B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $102.88 |
52-Week Low | $59.86 | $24.16 |
Enterprise Value | $91.98B | $5.37B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $92.49, up 3.11% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue grew to $22.67B in 2025, net income surged to $7.09B, and cash flow from operations hit $10.33B. Analyst consensus is strongly bullish with a $134.63 price target, though technical indicators show selling pressure near resistance at $92.
The outlook is positive given robust profitability, low P/E of 11.57, and gold price tailwinds, but risks include rising unit costs and production volatility. With 76% of analysts rating it Buy and institutional interest steady, NEM offers value if operational execution holds.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
